Kalvista Pharmaceuticals Inc (KALV) Given Average Rating of “Buy” by Analysts
Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have received a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $26.00.
KALV has been the topic of a number of recent research reports. Roth Capital initiated coverage on Kalvista Pharmaceuticals in a report on Tuesday, July 10th. They issued a “buy” rating and a $20.00 target price on the stock. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Wednesday, September 12th. Finally, Cantor Fitzgerald initiated coverage on Kalvista Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $32.00 target price on the stock.
In related news, Director Albert Cha bought 1,058,824 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 49.10% of the company’s stock.
Shares of KALV stock traded up $1.99 during mid-day trading on Friday, hitting $19.99. 1,294 shares of the stock traded hands, compared to its average volume of 112,541. Kalvista Pharmaceuticals has a twelve month low of $6.65 and a twelve month high of $18.90. The stock has a market cap of $204.54 million, a PE ratio of -12.54 and a beta of 3.07.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.14). The company had revenue of $3.72 million during the quarter, compared to analyst estimates of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. sell-side analysts predict that Kalvista Pharmaceuticals will post -1.69 EPS for the current year.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Story: Understanding Analyst Recommendations
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.